 | Gabriel N HortobagyiShow email addressFrom the Department of Breast Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston (G.N.H.), and Simmons Comprehensive Cancer Center, University of Texas ... |
Is this your profile? Claim your profile Copy URL Embed Link to your profile |
Gabriel N Hortobagyi:Expert Impact
Concepts for whichGabriel N Hortobagyihas direct influence:Breast cancer,Metastatic breast cancer,Neoadjuvant chemotherapy,Breast carcinoma,Adjuvant chemotherapy,Breast neoplasms,Metastatic breast,Breast cancer patients.
Gabriel N Hortobagyi:KOL impact
Concepts related to the work of other authors for whichfor which Gabriel N Hortobagyi has influence:Breast cancer,Neoadjuvant chemotherapy,Tumor cells,Bone metastases,Estrogen receptor,Gene expression.
KOL Resume for Gabriel N Hortobagyi
| Year | |
|---|---|
| 2022 | From the Department of Breast Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston (G.N.H.), and Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center (C.L.A.), and Baylor University Medical Center, Texas Oncology, US Oncology (J.O.), Dallas - all in Texas; the Institute of Oncology, Davidoff Center, Rabin Medical Center, Tel Aviv University, Tel Aviv, Israel (S.M.S.); Sarah Cannon Research Institute, Nashville (H.A.B.); the Department of Medical Oncology, National Cancer Centre Singapore, Singapore (Y.-S.Y.); the Department of Medical Oncology, Netherlands Cancer Institute and Borstkanker Onderzoek Groep Study Center, Amsterdam (G.S.S.); Florida Cancer Specialists, Sarah Cannon Research Institute, Fort Myers (L.H.); the Department of Medical Oncology, Institut de Cancérologie de l'Ouest-René Gauducheau, Saint-Herblain (M.C.), and the Department of Medical Oncology, Institut Gustave Roussy, Medical School, Université Paris-Saclay, Villejuif (F.A.) - both in France; the Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic (K.P.); the Department of Medical Oncology, Dana-Farber Cancer Institute, Boston (E.P.W.); the Department of Gynecology, University of Ulm, Ulm, Germany (W.J.); the Department of Surgery, Oncology, and Gastroenterology, University of Padua, and the Division of Medical Oncology 2, Istituto Oncologico Veneto, IRCCS, Padua, Italy (P.C.); the Edinburgh Cancer Research Centre, Institute of Genomics and Cancer, University of Edinburgh, Edinburgh (D.A.C.); Novartis Pharmaceuticals, East Hanover, NJ (J.P.Z., A.C.); and Novartis Pharma, Basel, Switzerland (T.T., F.L.G., P.S.). Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA |
| 2021 | University of Texas MD Anderson Cancer Center, Houston, Texas. MD Anderson Cancer Center, Houston, USA |
| 2020 | Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center Houston, Houston, TX 77030 USA University of Texas MD Anderson Cancer Center, Houston, TX; |
| 2019 | Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 1354, 77030, Houston, TX, USA MD Anderson Cancer Center, Houston, Texas |
| 2018 | Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. MD Anderson Cancer Center, Houston, Texas. |
| 2017 | Professor; Co‐Director, Breast Cancer Research Program, The University of Texas MD Anderson Cancer Center, Houston, TX. The University of Texas MD Anderson Cancer Center Houston Texas USA Department of Breast Medical Oncology, University of Texas, MD Anderson Cancer Center, Houston |
| 2016 | The University of Texas MD Anderson Cancer Center, Houston, USA Department of Breast Medical Oncology, University of Texas MD Anderson Cancer Center, Houston |
| 2015 | Department of Breast Medical Oncology at The University of Texas, MD Anderson Cancer Center, Houston, TX, USA. All authors: The University of Texas MD Anderson Cancer Center, Houston, TX. Gabriel N. Hortobagyi, University of Texas MD Anderson Cancer Center, Houston, TX; Nagi S. El-Saghir, American University of Beirut Medical Center, Beirut, Lebanon; Tanja Cufer, University of Ljubljana and University Clinic Golnik, Golnik, Slovenia; Eduardo Cazap, National Cancer Institute of Argentina, Latin American and Caribbean Society of Medical Oncology, Buenos Aires, Argentina; Roselle de Guzman, St Luke's Medical Center, Quezon City, the Philippines; Nicholas Anthony Othieno-Abinya, University of Nairobi, Nairobi, Kenya; Jose Angel Sanchez, Universidad Nacional Autonoma de Honduras, Tegucigalpa, Honduras; and Doug Pyle, American Society of Clinical Oncology, Alexandria, VA. M.D. Anderson Cancer Center, Houston (G.N.H.) University of Texas MD Anderson Cancer Center, Houston, Texas, USA; |
| Concept | World rank |
|---|---|
| tp53‐mutated breast cancers | #1 |
| pcr trastuzumab | #1 |
| pst rfs | #1 |
| s0800 neoadjuvant trial | #1 |
| platinum agents agents | #1 |
| paclitaxel predictive tests | #1 |
| lrr neo | #1 |
| development new lesions | #1 |
| clinical factors lrr | #1 |
| angiozyme0 | #1 |
| pocmf | #1 |
| liposomal doxorubicin gemcitabine | #1 |
| disease her2 | #1 |
| everolimus eve | #1 |
| ctcs polysomy | #1 |
| doxorubicinbased chemotherapy | #1 |
| neoadjuvant paclitaxel fluorouracil | #1 |
| erk tnbc | #1 |
| exemestane metformin | #1 |
| disease dose intensity | #1 |
| vinorelbine continuous infusion | #1 |
| positive ≥10 patients | #1 |
| patients novo stage | #1 |
| pea3 tumor growth | #1 |
| patients bct xrt | #1 |
| tumour response interpretation | #1 |
| wp fac | #1 |
| cxcr4 node metastasis | #1 |
| guided dasatinib therapy | #1 |
| cellular fitness phenotypes | #1 |
| 246±78 | #1 |
| pcr pcrdcis | #1 |
| sensitivity erlotinib | #1 |
| weekly everolimus | #1 |
| tyr907 | #1 |
| fac drfs | #1 |
| dfs hrd status | #1 |
| neoplasms docetaxel | #1 |
| treatment combination chemotherapy | #1 |
| metastatic tumors patients | #1 |
| bm cscs | #1 |
| patients mdapi score | #1 |
| usp11 neoadjuvant therapy | #1 |
| doxorubicin adjuvant chemotherapy | #1 |
| doxorubicin administered | #1 |
| metformin diabetic patients | #1 |
| patients mc disease | #1 |
| taxanebased chemotherapy | #1 |
| lmm ivt arac | #1 |
| vacp vbmf | #1 |
| Sign-in to see all concepts, it's free! | |
Prominent publications by Gabriel N Hortobagyi
Breast cancer is the most common cancer and the second leading cause of cancer death in American women. It was the second most common cancer in the world in 2002, with more than 1 million new cases. Despite advances in early detection and the understanding of the molecular bases of breast cancer biology, about 30% of patients with early-stage breast cancer have recurrent disease. To offer more effective and less toxic treatment, selecting therapies requires considering the patient and ...
| Known for Breast Cancer | Systemic Therapy | Treatment Resistance | Tumor Response | 30 Patients |
BACKGROUND: The 21-gene recurrence score assay is prognostic for women with node-negative, oestrogen-receptor-positive breast cancer treated with tamoxifen. A low recurrence score predicts little benefit of chemotherapy. For node-positive breast cancer, we investigated whether the recurrence score was prognostic in women treated with tamoxifen alone and whether it identified those who might not benefit from anthracycline-based chemotherapy, despite higher risks of recurrence.
METHODS: ...
| Known for Recurrence Score | Retrospective Analysis | Postmenopausal Women | Positive Breast | Benefit Chemotherapy |
BACKGROUND: Postmenopausal women with hormone receptor-positive (HR(+)) breast cancer in whom disease progresses or there is recurrence while taking a nonsteroidal aromatase inhibitor (NSAI) are usually treated with exemestane (EXE), but no single standard of care exists in this setting. The BOLERO-2 trial demonstrated that adding everolimus (EVE) to EXE improved progression-free survival (PFS) while maintaining quality of life when compared with EXE alone. Because many women with HR(+) ...
| Known for Elderly Patients | Hormone Receptor | Eve Exe | Breast Cancer | 65 Years |
Aberrant epidermal growth factor receptor (EGFR) signaling is a major cause of tumor progression and metastasis; the underlying mechanisms, however, are not well understood. In particular, it remains elusive whether deregulated EGFR pathway is involved in epithelial-mesenchymal transition (EMT), an early event that occurs during metastasis of cancers of an epithelial origin. Here, we show that EGF induces EGFR-expressing cancer cells to undergo a transition from the epithelial to the ...
| Known for Cancer Cells | Signal Transducer | Growth Factor | Gene Expression | Stat3 Twist |
BACKGROUND: The purpose of this retrospective study was to determine, in a cohort of patients with breast cancer and central nervous system (CNS) metastases, the effect of trastuzumab in patients with human epidermal growth factor receptor 2 (HER2)-positive disease and to compare this with that of patients with HER2-negative disease.
METHODS: Five hundred and ninety-eight patients with invasive breast cancer, CNS metastases and known HER2 status were identified. Time to CNS metastases ...
| Known for Cns Metastases | Breast Cancer | Trastuzumab Patients | Her2positive Disease | Monoclonal Antibodies |
PURPOSE: To compare rates of locoregional recurrence (LRR) after mastectomy, doxorubicin-based chemotherapy, and radiation with those of patients receiving mastectomy and doxorubicin-based chemotherapy without radiation and to determine predictors of LRR after postmastectomy radiation.
METHODS: Kaplan-Meier freedom-from-LRR rates were calculated for 470 patients treated with mastectomy, doxorubicin-based chemotherapy, and postmastectomy radiation in five single-institution clinical ...
| Known for Postmastectomy Radiation | Locoregional Recurrence | Lrr Patients | Based Chemotherapy | Breast Cancer |
Importance: The American Joint Committee on Cancer (AJCC) eighth edition staging manual introduced a new prognostic stage for breast cancer incorporating biologic factors in addition to traditional anatomic factors.
Objective: To perform a validation study of the AJCC eighth edition prognostic stage in a single-institution cohort and a large population database.
Design, Setting, and Participants: Patients with breast cancer treated with surgery as an initial intervention were identified ...
| Known for Prognostic Stage | Breast Cancer | Joint Committee | Eighth Edition | Median Followup |
BACKGROUND: The randomized, controlled BOLERO-2 (Breast Cancer Trials of Oral Everolimus) trial demonstrated significantly improved progression-free survival with the use of everolimus plus exemestane (EVE + EXE) versus placebo plus exemestane (PBO + EXE) in patients with advanced breast cancer who developed disease progression after treatment with nonsteroidal aromatase inhibitors. This analysis investigated the treatment effects on health-related quality of life (HRQOL).
METHODS: Using ...
| Known for Advanced Breast Cancer | Eve Exe | Life Hrqol | Hazard Ratio | Versus Placebo |
IMPORTANCE: The long-term effect of axillary pathologic complete response (pCR) on survival among women with breast cancer treated with primary systemic chemotherapy (PST) is unknown.
OBJECTIVE: To assess the long-term effect of axillary pCR on relapse-free survival (RFS) and overall survival (OS) in women with breast cancer with cytologically confirmed axillary lymph node metastases treated with PST.
DESIGN, SETTING, AND PARTICIPANTS: We retrospectively analyzed the effect of axillary ...
| Known for Axillary Pcr | Breast Cancer | Node Metastases | Rfs Patients | Pathologic Complete Response |
Phosphatase and tensin homolog (PTEN) is a key modulator of trastuzumab sensitivity in HER2-overexpressing breast cancer. Because PTEN opposes the downstream signaling of phosphoinositide 3-kinase (PI3K), we investigated the role of PTEN and other components of the PI3K pathway in trastuzumab resistance. We analyzed the status of PTEN, p-AKT-Ser473, and p-p70S6K-Thr389 using immunohistochemistry. PIK3CA mutation status was analyzed by direct sequencing. Primary tumor tissue was available ...
| Known for Trastuzumab Response | Pten Loss | Monoclonal Antibodies | Breast Carcinoma | Estrogen Receptors |
IMPORTANCE: The most appropriate dose fractionation for whole-breast irradiation (WBI) remains uncertain.
OBJECTIVE: To assess acute and 6-month toxic effects and quality of life (QOL) with conventionally fractionated WBI (CF-WBI) vs hypofractionated WBI (HF-WBI).
DESIGN, SETTING, AND PARTICIPANTS: Unblinded randomized trial of CF-WBI (n = 149; 50.00 Gy/25 fractions + boost [10.00-14.00 Gy/5-7 fractions]) vs HF-WBI (n = 138; 42.56 Gy/16 fractions + boost [10.00-12.50 Gy/4-5 fractions]) ...
| Known for Hfwbi Cfwbi | Breast Irradiation | Randomized Clinical Trial | Fatigue Patients | Conventionally Fractionated |
PURPOSE: The objective of this study was to determine whether the addition of trastuzumab to chemotherapy in the neoadjuvant setting could increase pathologic complete response (pCR) rate in patients with human epidermal growth factor receptor 2 (HER2) -positive disease.
PATIENTS AND METHODS: Forty-two patients with HER2-positive disease with operable breast cancer were randomly assigned to either four cycles of paclitaxel followed by four cycles of fluorouracil, epirubicin, and ...
| Known for Trastuzumab Chemotherapy | Operable Breast Cancer | Antibodies Monoclonal Antibodies | Growth Factor | Human Epidermal |
